If you have been reading about GLP-1 and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-04-14. Numbers and descriptions here follow the published literature rather than marketing material.
Clinical development of this compound followed earlier short-acting GLP-1 analogues that required frequent injection. Once-weekly subcutaneous formulations entered use after 2017, and an oral formulation using a permeation enhancer later became available. The oral version pairs the peptide with sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, a carrier that improves uptake across the gastric epithelium. Interest has expanded from glycaemic control into weight management and metabolic liver disease. Regulatory status and approved indications differ between countries, and the product remains subject to ongoing safety monitoring.
Semaglutide is a synthetic peptide that acts as an agonist at the glucagon-like peptide-1 receptor. It is a structural analogue of human GLP-1(7-37), modified to resist enzymatic degradation by dipeptidyl peptidase-4. The peptide backbone contains alpha-aminoisobutyric acid at position 8, a substitution that stabilises the helix and slows cleavage. A fatty diacid side chain attached through a linker at lysine 34 promotes binding to serum albumin, which extends the circulating half-life. These two modifications together allow less frequent administration than native GLP-1 requires.
Activation of the GLP-1 receptor couples to Gs signalling and raises intracellular cyclic AMP in pancreatic beta cells. The resulting insulin release depends on prevailing glucose concentrations, so the effect is greater when glucose is elevated. Receptor engagement also suppresses glucagon secretion and slows gastric emptying, which flattens post-meal glucose excursions. In the central nervous system, signalling in hypothalamic and brainstem regions is associated with reduced appetite and lower energy intake. Studies continue to examine effects on cardiac, renal and hepatic endpoints; whether those benefits are independent of weight change remains an open question.
Reconstituted solutions are less stable than the dry powder, and stability depends on concentration, pH, buffer composition, and container material. Low-protein-binding tubes reduce loss of peptide to plastic surfaces. Some researchers add a carrier protein to limit adsorption at low concentrations. The exact shelf life of a given solution is best determined empirically through a stability study rather than assumed from general guidance, because published data cover only a limited set of conditions.
Storage conditions for semaglutide depend heavily on the presentation. Lyophilized research powder is generally kept at two to eight degrees Celsius in a sealed container, protected from light and moisture. Manufacturer labeling for finished injectable products specifies refrigeration before first use, with defined in-use periods at room temperature afterward. The oral tablet form is stored at controlled room temperature and is more tolerant of short excursions. Temperature excursions should be documented rather than inferred.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C187H291N45O59 | Parent peptide; salt forms also reported |
| Molecular mass | about 4113.6 Da | Average mass of the free peptide |
| Peptide length | 31 amino acids | Backbone related to GLP-1(7-37) |
| Key substitution | Aib at position 8 | Blocks DPP-4 cleavage |
| Albumin binding | Via C-18 diacid side chain | Prolongs circulation time |
Two structural features account for the prolonged half-life of semaglutide. A modified amino acid at position 8 resists cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GLP-1. A fatty diacid side chain binds serum albumin, which limits renal clearance and protects the peptide from enzymatic breakdown. These modifications yield a plasma half-life of approximately one week in humans, allowing once-weekly administration. The relationship between plasma concentration and clinical effect varies between individuals, and sources of that variability are still being characterized.
Semaglutide is a synthetic peptide analog of glucagon-like peptide-1 (GLP-1), a hormone released from intestinal L-cells after food intake. The compound belongs to the incretin mimetic class and acts at GLP-1 receptors distributed across pancreatic, gastrointestinal, cardiovascular, and central nervous system tissues. Compared with native GLP-1, the molecule carries structural changes that extend its activity from minutes to roughly one week. It is studied for glycemic control in type 2 diabetes and for weight management, and its effects on cardiovascular and other outcomes remain active research areas.
Receptor binding triggers G protein signaling that raises intracellular cyclic AMP in pancreatic beta cells. Insulin release follows in a glucose-dependent manner, so secretion increases when blood glucose is elevated and diminishes when it is not. The same signaling suppresses glucagon release from alpha cells and slows gastric emptying, which blunts the post-meal glucose rise. In the brain, receptor activation in regions such as the arcuate nucleus is associated with reduced appetite and lower energy intake. How much each of these effects contributes to overall weight change is not fully settled.
The compound binds the GLP-1 receptor on pancreatic beta cells and other tissues, activating a G-protein signaling cascade that raises intracellular cyclic AMP. This action increases glucose-dependent insulin secretion when blood glucose is elevated, while binding also slows gastric emptying and reduces glucagon release. In the central nervous system, receptor activation in the hypothalamus and brainstem contributes to reduced appetite. The fatty acid chain binds albumin, which protects the peptide from renal filtration and enzymatic degradation. This albumin binding is central to its extended circulation time.
Native GLP-1 is degraded rapidly by dipeptidyl peptidase-4. Semaglutide resists this cleavage because alanine at position 8 is replaced by alpha-aminoisobutyric acid. A second substitution at position 34 introduces arginine, which further stabilizes the peptide. The most distinctive modification is a spacer and C18 fatty diacid attached at lysine 26, enabling strong albumin affinity. These three changes together produce a half-life measured in days rather than minutes, and the same structural logic underlies other long-acting analogs in this class.
Semaglutide is a synthetic peptide analog of glucagon-like peptide-1, a hormone released from intestinal L-cells after food intake. It contains 31 amino acids and differs from native GLP-1 through modifications that slow enzymatic breakdown. The peptide was developed to extend the short circulating half-life of endogenous GLP-1, which is measured in minutes. Researchers introduced the compound in the early 2010s. Two backbone changes and a fatty acid side chain define its structure, distinguishing it from earlier GLP-1 receptor agonists.
=== 2018–present: Cool Blue Jewels and Pink Python === On February 9, 2018, Riff Raff and DJ Afterthought released the album Cool Blue Jewels with features from Wiz Khalifa, Chevy Woods, Jimmy Wopo, Young Buck and Project Pat, among others. On November 9, 2018, Riff Raff released a mixtape titled Tangerine Tiger with guest appearances from Z-Ro, Lil Tracy, Ricki Rich among others. On April 12, 2019, Riff Raff released his third studio album titled Pink Python with guest appearances from Chief Keef, J-Dawg, and Killah Priest. Riff Raff premiered his single "Jazzmine" with the Houston Chronicle, a remake of "A Whole New World" from Aladdin featuring Iliana Eve, Jonathan Hay, Aneesa Badshaw, Ranna Royce and others. On October 25, 2019, Riff Raff released his fourth studio album titled Cranberry Vampire, with appearances from Simon Rex, Andy Milonakis, Chief Keef, and others.
== Alternative administration routes == Two routes of administration are currently clinically utilized: subcutaneous (either as intermittent injections or continuous infusion) and sublingual. Other non-invasive administration routes were investigated as a substitute for parenteral administration, reaching different preclinical and clinical stages. These include: peroral, nasal, pulmonary, transdermal, rectal, and buccal, as well as iontophoresis methods.
=== Alternative medicine === Despite the lack of evidence, castor oil is sometimes claimed to be able to cure diseases. According to the American Cancer Society, "available scientific evidence does not support claims that castor oil on the skin cures cancer or any other disease."
=== Cancer === Meta-analyses have been performed to examine the association between NQO1 polymorphism and increased cancer risk. The results from some of these analyses have been summarized in the table below:
=== Structure === Fialuridine is a synthetic pyrimidine nucleoside analogue with the molecular formula C9H10FIN2O5 and a molecular weight of 372.09 g/mol. Structurally, it consists of a substituted pyrimidine base covalently linked to a modified pentose sugar. The base component is a 5-iodo-substituted pyrimidine-2,4-dione ring. The pyrimidine ring is aromatic, containing two carbonyl groups at positions 2 and 4. The uracil derivative also contains an iodine atom at position 5. The attached sugar is a five-membered furanose ring that differs from natural deoxyribose in two ways: it has a fluorine atom at the second carbon (2-deoxy-2-fluoro substitution) and adopts the arabino configuration (fluor pointing up, 3’hydroxyl pointing down). The sugar ring is saturated and non-aromatic. The modified base and sugar are connected via a β-N1 glycosidic bond between the anomeric carbon of the sugar and the N1 nitrogen of the pyrimidine ring. All these structural features correspond to similar pyrimidine analogues.
Sources: en.wikipedia.org
The process of selecting appropriate deep final repositories for high-level waste and spent fuel is now underway in several countries with the first expected to be commissioned sometime after 2010. The basic concept is to locate a large, stable geologic formation and use mining technology to excavate a tunnel, or use large-bore tunnel boring machines (similar to those used to drill the Channel Tunnel from England to France) to drill a shaft 500 to 1,000 metres (1,600 to 3,300 ft) below the surface where rooms or vaults can be excavated for disposal of high-level radioactive waste. The goal is to permanently isolate nuclear waste from the human environment. Many people remain uncomfortable with the immediate stewardship cessation of this disposal system, suggesting perpetual management and monitoring would be more prudent. Because some radioactive species have half-lives longer than one million years, even very low container leakage and radionuclide migration rates must be taken into account. Moreover, it may require more than one half-life until some nuclear materials lose enough radioactivity to cease being lethal to living things. A 1983 review of the Swedish radioactive waste disposal program by the National Academy of Sciences found that country's estimate of several hundred thousand years—perhaps up to one million years—being necessary for waste isolation "fully justified." The proposed land-based subductive waste disposal method disposes of nuclear waste in a subduction zone accessed from land and therefore is not prohibited by international agreement.
== Subfamily B3 == Subfamily B3 includes Methuselah and other Drosophila proteins. Other than the typical seven-transmembrane region, characteristic structural features include an amino-terminal extracellular domain involved in ligand binding, and an intracellular loop (IC3) required for specific G-protein coupling.
The decisive victory of Lieutenant-General Bernard Montgomery's Eighth Army over the Germans and Italians at the Second Battle of El Alamein in October–November 1942 turned the tide of the North African war strongly in favour of the Allies, and did much to revive Allied morale. The Rhodesians of the KRRC took part in the battle as part of the 7th Armoured Division under the XIII Corps, forming part of the initial thrust in the southern sector. The Rhodesian Anti-Tank Battery under Major Guy Savory also fought at El Alamein, supporting the Australian 9th Division as part of the XXX Corps. The fighting around "Thompson's Post" between 1 and 3 November was some of the fiercest Rhodesians took part in during the war. Hoping to knock out the Allied anti-tank guns before counter-attacking, the Germans concentrated intense artillery fire on the Australian and Rhodesian guns before advancing 12 Panzer IV tanks towards the weakest point of the Australian line. The Australian six-pounders had been largely disabled by the bombardment but most of the Rhodesian guns remained operational. The Rhodesian gunners disabled two Panzers and seriously damaged two more, compelling an Axis retreat, and held their position until being relieved on 3 November. One Rhodesian officer and seven other ranks were killed and more than double that number were wounded. For his actions at Thompson's Post, Sergeant J A Hotchin received the Distinguished Conduct Medal; Lieutenants R J Bawden and H R C Callon won the Military Cross and Trooper P Vorster the Military Medal.
To diagnose LMS, a physical exam may be performed by one's physician, imaging tests such as MRI, CT, and PET scans can be performed, or tissue biopsies can also be completed where the histopathology of the removed tissue sample is examined.
== Further reading == Gregory, Kelvin B.; Bond, Daniel R.; Lovley, Derek R. (June 2004). "Graphite electrodes as electron donors for anaerobic respiration". Environmental Microbiology. 6 (6): 596–604. Bibcode:2004EnvMi...6..596G. doi:10.1111/j.1462-2920.2004.00593.x. ISSN 1462-2912. PMID 15142248.
Sources: en.wikipedia.org
=== Autoimmune diseases === Problems posed by the differences in the human and rodent immune systems have been overcome using a few strategies, so as to enable researchers to study autoimmune disorders using humanized models. As a result, the use of humanized mouse models has extended to various areas of immunology and disease research. For instance, humanized mice have been utilized to study human-tropic pathogens, liver cancer models, and the comparison of mouse models to human diseases NSG mice engrafted with PBMCs and administered with myelin antigens in Freund's adjuvant, and antigen-pulsed autologous dendritic cells have been used to study multiple sclerosis. Similarly, NSG mice engrafted with hematopoietic stem cells and administered with pristane have been used for studying lupus erythematosus. Furthermore, NOG mice engrafted with PBMCs has been used to study mechanisms of allografts rejection in vivo. The development of humanized mouse models has significantly advanced the study of autoimmune disorders and various areas of immunology and disease research. These models have provided a platform for investigating human diseases, immune responses, and therapeutic interventions, bridging the gap between human and rodent immune systems and offering valuable insights into disease pathogenesis and potential therapeutic strategies.
She has also been involved in creating a new zebrafish model to study the role of glutathione S-transferase π1 in development, redox homeostasis, and drug response involving cytotoxicity through endoplasmic reticulum stress and unfolded protein response. Additionally, in an Antioxidants & Redox Signaling review, she analyzed the influence of the S-glutathionylation cycle on protein structure, cellular regulation, and its significance for interventions in stress- and aging-related pathologies. Furthermore, her research has demonstrated that altered GSTP expression within the endoplasmic reticulum regulates protein homeostasis (proteostasis) through S-glutathionylation of ER resident proteins, including PDI and BiP. GSTP leads to S-glutathionylation of binding immunoglobulin protein (BiP), contributing to acquired resistance to Btz in multiple myeloma (MM) cells, representing a novel mechanism of drug resistance in MM. She has also emphasized GSTπ's novel role in enhancing S-glutathionylation reactions under oxidative and nitrosative stress, with implications for stress response and drug resistance in tumors.
== Philosophy, origins, architects == The international drug conventions occurred within the newly formed United Nations, as the UN assumed the duties of the retired League of Nations after WWII. The preamble to the Single Convention establishes the overarching concern of the drug treaties as "the health and welfare of mankind". It recognizes "narcotic drugs" as "indispensable for the relief of pain and suffering" and that they "must be made [available] for such purposes". It also recognizes addiction to narcotics as "a serious evil for the individual and is fraught with social and economic danger to mankind" and that there is a duty of nations to "prevent and combat this evil". The conventions offer a degree of interpretative flexibility within a framework of control through prohibition. Controlled substances used for medical and scientific purposes are regulated, while other uses are prohibited; "each of the treaties encourages – and often requires – that member countries put in place strong domestic penal provisions." A report by the Library of Parliament for the government of Canada on the history of the conventions identifies four themes as critical influences on the nature of the treaties: prohibition, United States involvement, external influences, and the outsized impact of certain powerful individuals. Prohibition of illicit use, "as opposed to regulation", has been the central philosophy. The US has been "the key player in most multilateral negotiations" and the prohibitionist approach "derives largely from U.S.
If two vertices have the same mass difference of one or several amino acids, a directed edge will be applied. The SeqMS algorithm, Lutefisk algorithm, Sherenga algorithm are some examples of this type.
Sources: en.wikipedia.org
It belongs to the incretin mimetic class and acts as a long-acting glucagon-like peptide-1 receptor agonist. The class includes several peptides with different half-lives and routes of administration.
The side chain enables reversible binding to albumin in the bloodstream, which protects the peptide from rapid renal clearance. This extends the interval between administrations compared with unmodified GLP-1.
No. It shares much of the native sequence but carries substitutions and an added side chain. These changes increase stability against enzymatic breakdown.
Sealed, protected from light, and refrigerated at two to eight degrees Celsius for most research material. Desiccated storage limits moisture uptake. Allow the vial to reach room temperature before opening to prevent condensation.